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What is damaging the kidney in lupus nephritis?
Anne Davidson, MBBS
Center for Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research,
Manhasset, New York, NY 11030*

Summary
Author Manuscript

Despite marked improvements in the survival of patients with severe lupus nephritis over the last
50 years the rate of complete clinical remission following immune suppression is less than 50%
and renal impairment still occurs in 40% of affected patients. An appreciation of factors leading to
the development of chronic kidney disease (CKD) following acute or subacute renal injury in
lupus patients is beginning to emerge. Processes that contribute to endstage renal injury include
continuing inflammation, activation of intrinsic renal cells, cell stress and hypoxia, metabolic
abnormalities, aberrant tissue repair and tissue fibrosis. This understanding is leading to the
development of novel or adjunctive therapies that may protect from the secondary non-immune
consequences of acute injury. Approaches based on a molecular/proteomic/lipidomic classification
of disease should yield new information about the functional basis of disease heterogeneity so that
the most effective and least toxic treatment regimens can be formulated for individual patients.

Author Manuscript

Introduction

Author Manuscript

Lupus nephritis (LN) affects 30–60% of adults and up to 70% of children with systemic
lupus erythematosus (SLE) and is characterized by the glomerular deposition of immune
complexes followed by recruitment of an inflammatory response. Glomerular disease is
classified by light microscopy into five histologic subtypes of which classes III–V have the
potential for long term damage. Further histologic classification uses composite scores for
active inflammation and chronic scarring (1–5). Although classification drives therapeutic
decision-making, the current scheme does not adequately predict which patients will
respond to therapy (3, 6–7), indicating that additional phenotyping based on mechanisms of
tissue injury is required. In addition, patients in clinical remission may exhibit progressive
inflammation and fibrosis in repeat biopsies suggesting that improved disease monitoring
could prevent undertreatment of subclinical disease (8–9).
While advances in immunosuppressive regimens and general medical care have erased most
of the differences in long-term outcomes between proliferative and membranous LN (7, 10–
11), the rate of complete remission for proliferative disease remains below 50% (12–14), and
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up to 40% of LN patients still develop some degree of renal impairment (11, 14). This
failure of immunosuppressive agents to adequately treat LN, even in the setting of wellmonitored clinical trials, reflects an incomplete understanding of disease pathogenesis.
Either immune cell proliferation is not the only relevant cause of renal injury, or there is a
therapeutic time window after which this type of intervention is no longer effective.
In the first section of this review I will discuss current knowledge of LN pathogenesis
including disease initiation by immune complexes, immune activation in the kidney, and the
responses of renal parenchymal cells to this insult. In the second part I will discuss
approaches to identifying new pathogenic mechanisms, and review alternate ways to classify
and monitor disease that include molecular and proteomic analyses. Finally I will address
how these concepts may lead to improved therapies.

Author Manuscript

Mechanisms of renal damage
Initiation of inflammation by immune complexes

Author Manuscript

LN is initiated in most cases by the glomerular deposition of IgG and complement. Rarely,
LN occurs in the absence of immune complexes, presumably due to direct damage by
soluble inflammatory mediators (15). Sources of immune complexes include circulating
anti-nuclear, anti-C1q, and crossreactive anti-glomerular autoantibodies (16–20), opsonized
apoptotic particles, microparticles, and neutrophil NETs (21–22). Particulate DNA such as
that within neutrophil NETs can be resistant to digestion by DNAse (22), and
downregulation of renal DNAse I can be a late feature of disease (23). Although antibodies
eluted from LN kidneys are enriched for anti-DNA activity, not all anti-DNA antibodies are
pathogenic. Furthermore, non-DNA binding antibodies, some arising in situ, also contribute
to renal disease (24–25). This heterogeneity of renal depositing antibodies limits the ability
of serum antibody profiles to predict LN flares (26).

Author Manuscript

Immune complexes initiate renal damage by several mechanisms (Figure 1). Complexes that
deposit in the subendothelium injure endothelial cells and are the hallmark of Class III and
IV proliferative disease. These deposits have access to the vascular space and may activate
circulating myeloid cells that express Fc receptors, allowing them to infiltrate the renal
tissue (27). By contrast, subepithelial deposits, found in Class V disease, injure podocytes
but elicit a less severe inflammatory response as they contact only the urinary space. If the
glomerular basement membrane ruptures however, these immune complexes can access the
whole glomerulus. Immune deposits may initiate the complement cascade, or they may
directly activate intrinsic glomerular cells (28–29), inducing the release of inflammatory
chemokines and cytokines. Complexes containing nucleic acids additionally activate
intracellular TLRs, thereby enhancing the inflammatory response.
Immune mechanisms of tissue injury
Soluble inflammatory mediators—Following immune complex deposition, a large
variety of inflammatory mediators is produced in LN kidneys with spreading of the response
as disease progresses (28, 30). Several locally produced cytokines and chemokines that
contribute to inflammatory damage and whose absence or inhibition greatly attenuates
disease activity have been identified. Examples include CCL2, a chemokine expressed early
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in the glomerulonephritis process, and TNF that is expressed at proteinuria onset (31–32). A
Type I IFN signature is also a feature of LN kidneys (33–34). IFN has multiple detrimental
effects on the kidneys including vascular rarefaction and injury to glomerular parietal cells
and podocytes (35–36). Once tissue injury occurs, soluble products released from injured
cells amplify the inflammatory response by stimulating extracellular and intracellular innate
immune receptors (37–41). Podocytes, for example, are sensitive to TLR-mediated signals
and other inflammatory mediators such as NO, which induce foot process effacement and
podocyte loss (42). Nevertheless, not all renal inflammatory mediators are necessary for the
inflammatory process. For example, IL-17 deficiency alters the course of LN only in some
models in which TH17 cells infiltrate the kidneys (43–44). Thus, targeting of single
inflammatory mediators may not be sufficient to reverse the established renal inflammatory
response that becomes more complex over time.

Author Manuscript

Cellular infiltrates—Inflammatory cells may infiltrate the kidney through glomerular or
interstitial blood vessels. The anatomic organization of these infiltrates is quite variable.
They may consist of scattered cells, disorganized aggregates, or rarely, organized structures
containing germinal centers (45). There is also evidence for in situ activation of pathogenic
adaptive immune responses to degraded or modified renal antigens. Both B cells and T cells
from LN kidneys are clonally expanded, and the same T cell expansions have been detected
in the peripheral blood (46–47). Multiple T cell cytokines such as IFNγ, IL-21 and IL-17
have also been detected in LN kidneys (48), and T cells appear in the urine of LN patients
(49). In a small exploratory study, clonal CD8 T cell infiltrates were found adjacent to
epithelial cells in LN biopsies and were associated with more severe disease, suggesting an
effector function elicited by local antigens (47).
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Strikingly, a measurable proportion of B cells derived from human LN biopsies recognize
vimentin, an intracellular structural protein that is cleaved and extruded from apoptotic cells
(46). Serum anti-vimentin antibodies are associated with decreasing GFR and increasing
tubulointerstitial damage in other forms of CKD, and are similarly associated with severe
interstitial disease in LN (46, 50). Autoantibodies to annexin1 and αenolase have also been
detected in LN kidneys (51). These local adaptive immune responses may amplify
inflammation independently of systemic autoimmunity.

Author Manuscript

Macrophages play a central role in both injury and repair; renal infiltration of LN kidneys
with macrophages, particularly at the second biopsy, is associated with poor prognosis (52–
54). Both infiltrating inflammatory macrophages and resident interstitial macrophages may
be present in diseased kidneys (53, 55–56). Macrophages recruited from the peripheral blood
are pro-inflammatory during acute inflammation but can then switch to a reparative
phenotype (53, 57). Resident interstitial macrophages may have self-renewal properties (58),
and in mouse models of chronic LN, they increase in number, become activated, and acquire
MMP and cathepsin activity, suggesting that they contribute to aberrant tissue remodeling
(30, 55).
It is increasingly recognized that several types of dendritic cells also infiltrate the kidneys
during LN (59) potentially propagating local adaptive immune responses (60). Importantly,
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an increase in both CD141hi and myeloid DCs is observed in human glomerulonephritis
biopsies and correlates with fibrosis (61).
Non-immune mechanisms of tissue injury in LN
Several lines of evidence suggest that non-immune mechanisms of renal damage need to be
therapeutically addressed in LN. First, many patients do not adequately respond to
immunologic interventions. Second, remission can take months, during which time damage
may continue to accrue. Third, progression may occur even if systemic autoimmunity is
controlled. Although the role of each intrinsic renal cell during the stages of injury and
repair is still not fully understood, some general mechanisms of CKD should also be
applicable to LN (Figure 2).

Author Manuscript

Disruption of cell-cell interactions—Maintenance of the complex structure of the
nephron requires cell-cell interactions (62) (Figure 1). In the glomerulus, endothelial cells
directly contact mesangial cells (63). Mesangial cells sequester latent TGFβ, preventing
TGFβ-mediated damage to endothelial cells (64). Endothelial cells produce PDGF-B whose
interaction with PDGF-Rβ on mesangial cells is required for glomerular development.
Expression of PDGF isoforms is upregulated in many forms of renal injury, causing
mesangial hyperproliferation, matrix production, cytokine and chemokine release, and renal
fibrosis (65).

Author Manuscript

Podocytes and endothelial cells also interact by bidirectional diffusion of cytokines/growth
factors through the glomerular basement membrane (63). Podocytes secrete angiopoietin 1
and VEGF-A that support endothelial cell survival; loss of renal VEGF-A characterizes LN
both in humans and mouse models and distinguishes LN from other forms of CKD (34). In
diseased tissue, both activated glomerular endothelial cells and damaged podocytes release
endothelin 1 that amplifies glomerular injury by causing mitochondrial stress (66). Since
podocyte regenerative capacity is limited in adults, loss of podocytes eventually leads to
glomerulosclerosis. As nephrons are lost, compensatory mechanisms cause a rise in
intraglomerular pressure and glomerular stress in the remaining nephrons (67).

Author Manuscript

A cell that has received much recent attention is the pericyte which contacts and shares a
basement membrane with capillary endothelial cells. Pericytes secrete VEGF-A, chemokines
and other inflammatory mediators, they help maintain endothelial cell quiescence, they
contribute to the basement membrane and they regulate both medullary blood flow and cell
traffic through the endothelial barrier during inflammation (68–70). Mesangial cells are the
pericytes of the glomerulus and the interstitium has its own pericyte network attached to
tubular capillaries. During inflammation, these pericytes rapidly dissociate from tubular
capillaries and migrate into the interstitial space where they differentiate into myofibrobasts
(71).
Abnormal vascular function and tissue hypoxia—Glomerular endothelial cells are
coated with a glycocalyx layer that forms a crucial barrier to protein loss (72); this barrier
can be degraded by the enzyme heparanase that is induced by endothelial hypoxic stress
(73). As pericytes dissociate from capillaries and VEGF-A production diminishes, the
capacity for angiogenesis and capillary repair is lost, leading to capillary rarefaction in both
Nat Rev Rheumatol. Author manuscript; available in PMC 2017 March 01.
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the glomerulus and the interstitium (71, 74). Other disturbances of angiogenesis reported in
LN include a decrease in the ratio of pro-angiogenic Ang1/anti-angiogenic Ang2,
downregulation of the angiogenic factor FGF-2, an increase in the VEGF inhibitor
ADAMTS-1, and alterations in endothelial nitric oxide synthase (68, 75–77). In a mouse
model of LN, downregulation of VEGF-A and FGF-2 persists even after induction of
complete remission, suggesting that vascular injury is not completely reversible (30).

Author Manuscript

Some areas of the kidney, especially the medulla, maintain a low pO2 even under normal
physiologic conditions and are sensitive to hypoxia. The interstitial blood supply derives
from post-glomerular blood vessels, so glomerular hypertension and sclerosis can cause
interstitial ischemia. Loss of VEGF-A, oxidative stress due to inflammation, increased
energy demands, endothelial cell injury by cytokines, enhanced endothelin release,
hypertension and anemia may all contribute to hypoxia (78–80); the relative contribution of
each of these mechanisms is not well understood.
Tubular dysfunction and atrophy—Ischemia, hypertension or failed regeneration
contribute to atrophy of tubular epithelial cells; such injury promotes both interstitial
immune cell infiltrates and fibrosis. Recent studies have shown that injured renal tubular
cells have a defect in fatty acid oxidation which causes mitochondrial dysfunction,
reprograms them to a pro-fibrotic phenotype, and contributes to their death (30). The defect
can be reversed by tubule-specific expression of the mitochondrial biogenesis regulator
PGC-1α. Importantly, human fibrotic kidneys have a similar alteration in tubular fatty acid
metabolism, suggesting a potential new therapeutic approach (81–82).

Author Manuscript

Renal fibrosis and progression to chronic kidney disease—Renal fibrosis is a
poor prognostic feature in LN as in CKD generally. The extent of fibrosis is determined by
the balance of matrix production with enzyme-mediated matrix breakdown and turnover
(83). Mesangial cells are the classical myofibroblasts in the glomerulus, but parietal
epithelial cells and podocytes may also contribute (83). In the interstitium, pericytes and
resident fibroblasts are the major sources of myofibroblasts that produce extracellular
matrix, MMP inhibitors and collagen (84). Both tissue macrophages and tubular epithelial
cells produce growth factors that support myofibroblast differentiation, including TGFβ,
PDGF and CTGF (85–86). These factors are balanced by local anti-fibrotic factors such as
the TGFβ antagonists BMP-7 and hepatocyte growth factor. In addition, cytokines,
chemokines, matrix proteins, procoagulants and remodeling enzymes produced by
inflammatory cells, tubular cells and macrophages provide a pro-fibrotic microenvironment
(87).

Author Manuscript

Although it has not been shown unequivocally that an area of fibrosis will damage adjacent
healthy nephrons (88), several lines of evidence indicate that fibrosis can amplify renal
damage. Fibroblasts may contribute to tissue injury by producing pro-inflammatory
mediators (89). Fibrotic tissue may disrupt normal anatomic structures and interfere with
oxygen diffusion, thus exacerbating hypoxia (83). In addition, epigenetic changes can
reprogram fibroblasts to maintain their profibrotic state even after inflammation has resolved
(90–92). One epigenetic change that has received considerable attention is the upregulation
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of miR-21 that protects against acute renal inflammation and damage but may also
exacerbate fibrosis (93–94).

Identifying novel pathways that contribute to initiation and progression of
lupus nephritis
Improved therapy for SLE will likely require disease classification based on pathogenic
mechanisms. Some of these mechanisms will be common to most patients, some may be
stage-specific, and others may apply to smaller patient subgroups or even individuals.
Several approaches to identify commonly shared pathways have been explored.
Clinical and Epidemiologic studies

Author Manuscript

Factors associated with poor outcomes in lupus nephritis are shown in Table 1 (11, 95–96).
Long term outcome depends on the degree of treatment response, with resolution of
proteinuria being the best surrogate marker of a favourable prognosis (97–98). The severity
of renal damage at presentation, manifested by serum creatinine and the degree of interstitial
inflammation and fibrosis, strongly influences the response to treatment. These data support
the need for improved monitoring of high risk individuals, and suggest that early detection
of LN and prompt intervention will improve outcomes. Not surprisingly, non-response to
therapy, recurrent flares and residual inflammation or fibrosis at repeat biopsy are associated
with a poorer prognosis (54, 99–100). Repeat biopsies are not routinely performed but may
be useful to guide tapering regimens and/or the need for changes in maintenance therapies.

Author Manuscript

Importantly, recent epidemiologic data from the US has shown an increase in ESRD in
uninsured individuals and in geographic areas with poor access to ambulatory care,
indicating a significant effect of healthcare policy, healthcare access and patient compliance
on LN outcomes (101). Similar results have been shown in other countries (102). Unless this
public health issue is addressed it is difficult to envision improved outcomes by medical
management alone.
Genetic risk for LN

Author Manuscript

Genome-wide analyses (GWAS)—A recent meta-analysis of 3 GWAS identified
several inherited polymorphisms that predispose to initiation of LN, including the PDGFRA
locus, the glucose transporter Slc5A11, and hyaluronan synthase 2 that is involved in
extracellular matrix formation (103). Other risk genes include ABIN1, TNFSF4, Stat4,
ITGAM, kallikreins and FcγRIIIa low-binding alleles (104–110). These results suggest a
link between inflammation and LN as well as a contribution from pathways that regulate the
renal response to inflammation and injury. However the relative risk associated with most of
these genetic variants is low, and some are relevant only in certain ethnic populations,
making it challenging to generate a clinically meaningful genetic risk-prediction test. The
function of the various polymorphisms will need to be unravelled in order to understand
their clinical significance.
Only a few small studies have addressed the genetic risk for increased disease severity in LN
patients. Polymorphisms in APOL1 and MYH9 confer an increased risk of renal failure in
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other chronic renal diseases, and appear to confer a modest risk for LN progression that may
be dependent on ethnicity (111–113). No studies have addressed the genetic basis for
responsiveness to therapy.

Author Manuscript

Local epigenetic changes—The epigenetic landscape of renal injury is just starting to
be described, particularly in the interstitium (114–115). Examples relevant to LN include
chromatin structure modifications that regulate the production of CCL2 and TNF, DNA
demethylation that regulates C3 production and histone acetylation that regulates the
production of PDGF and pro-fibrotic genes (115). Histone deacetylase inhibitors alleviate
progression in multiple models of renal injury and fibrosis by preventing cytokine release
and cell apoptosis and by inducing the protective molecule BMP-7 (116–117). Epigenetic
changes can also be mediated by non-coding RNAs. TGFβ induces several miRNAs that
enhance pro-fibrotic genes while at the same time inhibiting miRNAs that are protective
(93–94). The utility of blood and urine miRNA signatures as biomarkers for LN is starting to
be examined (118–119).
Molecular and proteomic signatures of renal disease
Molecular and/or proteomic phenotyping of the kidney or urine may identify the
immunologic and/or injury process currently affecting each individual, and could deliver
biomarkers to improve patient stratification for clinical trials and a more rational therapeutic
approach.

Author Manuscript
Author Manuscript

Molecular profiling of LN kidneys—Several studies have shown signatures of immune
cell infiltration and activation, extracellular matrix formation and fibrosis, endothelial cell
activation, fibrinolysis, mitochondrial dysfunction, and tubular injury (34, 120–121).
Because pre-nephritis and repeat biopsies are rarely available from humans, mouse models
have been useful for characterizing renal molecular profiles at sequential disease stages.
Overlay of these data onto data from human LN biopsies allows identification of pathways
that are relevant to human disease. Using this approach in NZB/W lupus-prone mice we
identified two dominant gene clusters that are dynamically regulated during disease
progression; the first is detected at proteinuria onset and reflects the inflammatory
component of nephritis – the second occurs during established proteinuria and reflects the
mitochondrial and metabolic signature of chronic disease. Remission induction therapy
administered promptly after nephritis onset reverses most of this abnormal gene expression
profile but we noted that the mitochondrial and metabolic signature recurred before clinical
relapse, perhaps reflecting an increased propensity to tissue hypoxia conferred by the initial
tissue insult (30). By following mice from remission to relapse, we further identified
podocyte loss, renal tubular dysfunction, endothelial cell activation and tissue remodeling as
the functional features associated with the progression to renal failure (30). Some of these
processes may be resistant to standard immune suppression (34, 122).
One important observation in mice is that glomerular disease does not always progress to
tubular and endothelial dysfunction (123–124). For example, BAFF deficient or BAFF-R-Ig
treated lupus-prone mice have autoantibodies, glomerulonephritis and interstitial
inflammatory infiltrates but do not die of renal failure (30, 123). Similarly, a genetic model
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has been generated in which acute glomerular injury occurs, but progression to CKD does
not (125). How this transition from renal inflammation to renal failure is regulated is not
completely understood (126–128) and is an important knowledge gap that needs to be filled
(121–123). In addition, there are several LN models in which renal deposition of immune
complexes does not induce the recruitment of effector cells. These include myeloid cell
deficiency of Fc receptors, CCL2 deficiency and intense costimulatory blockade (27, 129–
130). These studies, in sum, suggest that there are several opportunities for therapeutic
intervention that target the effector response in the kidney, regardless of systemic
autoimmunity.

Author Manuscript

A problem with the interpretation of molecular profiles of whole tissues is that the signatures
are biased towards the most frequent cell types and towards infiltrating cells that are rare in
normal kidneys. The only way to overcome these biases is to study each cell type
individually. No studies of this type have as yet been performed in human LN biopsies and
even the data from mouse models is still quite limited. Molecular studies in both mice and
humans have suggested that macrophages/DCs are key players in the development of LN
(34). Comparative molecular profiling of isolated renal macrophages from young and
nephritic NZB/W mice and NZW/BXSB mice (34, 55) revealed that several functional
pathways are upregulated in nephritic macrophages including the alternate complement
pathway, cell adhesion, phagocytosis and efferocytosis, Fc receptor signaling, the nucleic
acid sensing pathway and tissue repair. Pathways that are downregulated include fatty acid
metabolism and angiogenesis. This profile suggests aberrant resolution of inflammation
which may be driven by ongoing immune complex deposition and/or tissue damage. It
remains to be determined whether it is possible to harness the reparative function of
macrophages for optimal tissue repair without fibrosis.

Author Manuscript
Author Manuscript

Proteomic analysis of LN kidneys—Proteomic analysis of kidneys has been
challenging due to the limited amount of available tissue and the inability to detect small or
low abundance proteins; the feasibility of this approach is increasing with new technical
advances. A proteomic analysis of human lupus glomeruli revealed loss of podocyte
proteins, activation of the alternate complement pathway, loss of anti-oxidants and
downregulation of normal metabolic pathways, consistent with the findings of the molecular
studies (131–132). Analyses of proliferative LN biopsies using a targeted set of 500 immune
response genes showed that activation of IFN pathways, production of IL-10 and T and B
cell signaling pathways are associated with lack of response to therapy (6). These data are
consistent with the clinical observation that interstitial infiltrates are associated with poor
prognosis. It is also becoming clear that variability in the renal proteome can occur within a
WHO Class, adding potential for subclassification based on proteomic analysis (133).
In sum, the preliminary molecular and proteomic studies of LN kidneys have extended
mechanistic knowledge beyond the histologic data by identifying two phases of disease
characterized by inflammation and metabolic dysfunction, have identified both shared and
unique effector signatures and have identified a number of checkpoints along the path to
irreversible renal damage that could potentially be targeted by new therapies. The molecular
studies have been less successful at identifying the earliest features of LN since only few
genes are upregulated in the kidneys prior to the onset of proteinuria (30); a proportion of
Nat Rev Rheumatol. Author manuscript; available in PMC 2017 March 01.
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these is associated with steroid and lipid metabolism. Proteomic and metabolomic studies
may be more suitable for detecting such early changes (134–135).
Analysis of urines—Longitudinal monitoring of urine offers a window into the kidney
that could be used for treatment decisions. The technical challenges inherent in this
approach have recently been reviewed (133). The major clinical use of urine proteomics has
so far been to identify biomarkers that either predict an impending renal flare (6, 136) or
identify response to therapy. There are several longitudinal studies of single urine
biomarkers including the chemokine CCL2, the tubular marker lipocalin2, the acute phase
protein hepcidin and the TNF-like molecule TWEAK (reviewed (133, 137)). These studies
are still preliminary and have not yet been reliably reproduced or tested in the setting of a
clinical trial. Combination panels of these and other potential biomarkers identified in crosssectional studies may have a higher predictive value than single analytes alone.
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It is important to note that cells and microparticles of cells are also shed into the urine during
inflammation and this could be exploited for discovery of other protein and RNA-based
biomarkers and for early detection of podocyte loss.

Author Manuscript

Using therapeutics to test the pathogenicity of target molecules—A final
approach to identifying key pathways in LN is to identify molecules that are potentially
pathogenic based on their known biology and then test their role in pre-clinical models either
by genetic depletion or therapeutic targeting. This approach is often successful when the
correct preclinical model expressing the protein of interest is used and the treatment is timed
either before or at the first presentation of LN (138). Nevertheless this is proving to be a
cumbersome and expensive approach in human LN that has been hampered by the
primitiveness of disease phenotyping, the confounding effects of standard medications such
as glucocorticoids and the absence of a uniformly accepted definition of renal outcome
(139).
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When choosing such targets, it is important to consider the sometimes opposing effects of
pleiotropic immune pathways and cytokines on systemic immunity vs. local effector
responses. Genetic deficiencies of TNF, TGFβ, components of the innate pathway such as
TLR9 and STING and Nox2, and inflammasome components NLRP3 and ASC all induce or
exacerbate autoimmunity in mice (140–142). This may be due to the loss regulatory
functions of these proteins or to diminished capacity to fully control infectious insults. On
the other hand both TNF and TGF beta are highly expressed in inflamed kidneys and their
inhibition at this stage of disease improves disease outcome in mouse models (32, 143). TNF
inhibition does indeed improve chronic LN in patients without inducing systemic flares
although its clinical utility has been limited by other toxicities (144). Nevertheless, targeting
these types of pathways will need to be approached with caution.

Implications for treatment
Targeting systemic autoimmunity
Given the role of systemic autoimmunity in the initiation of LN, a major focus of
management should be on prevention. Indeed in mouse models of lupus, LN can be
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completely prevented by immune interventions that prevent the renal deposition of
autoantibodies or by genetic manipulations that prevent tissue responses to immune complex
deposition (145). There are however many obstacles to a similar approach in humans
including the heterogeneity of immune responses in individual patients, the absence of noninvasive monitoring tools for early detection, the potential toxicities of new therapies in
patients with quiescent disease and the expense of time-to-flare studies that need large study
cohorts.

Author Manuscript

Once disease onset occurs, there may only be a limited time window before disease
mechanisms that are insensitive to preventive strategies arise. In mice it is much easier to
prevent disease onset than to treat established disease with drugs that target T or B
lymphocytes and in some strains drug combinations are needed to induce remission (138,
145). Delay in diagnosis and treatment may result in the recruitment of inflammatory
amplification circuits or the onset of metabolic or structural changes in the kidneys that are
difficult to reverse with immunotherapy. Variability in treatment responses may also be due
to intrinsic differences between patients. Considerable variations in responses to
immunotherapy are observed in different mouse models of LN even when intervention is
initiated at disease onset (138); this may reflect heterogeneity in the severity of
inflammation, the relative involvement of innate vs. adaptive immune pathways, the balance
of inflammation vs. metabolic abnormalities and the degree of tissue hypoxia, nephron loss
and tubular regenerative capacity (Figure 3).
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Although biologic agents have not yet been successful in patients with LN (146–147) many
new approaches remain to be tested (146, 148). Obvious targets include key cytokines
expressed in inflamed kidneys such as IL1, IL6, M-CSF, IFNγ, Type I IFN, BAFF, IL17 and
IL21, signaling pathways such as tyrosine kinases, costimulatory molecules such as ICOS
and TWEAK (149) and effector molecules such as those in the complement pathway
(reviewed (150)). Chemokines are also appealing targets but despite extensive efforts have
not yet successfully been translated to human autoimmune disease (151–152). One
successful pilot approach has been to deplete plasma cells with a proteasome inhibitor, thus
clearing immune complexes and allowing the kidney to heal (153). Nevertheless, the overall
experience with immune suppression shows that non-immune based approaches to
preventing disease progression (154) also need to be considered in order to optimize the
resolution and repair process (Table 2). This field is still in its infancy but new approaches
are being tested and developments in this field may also be applicable to LN.
Targeting endothelial cell dysfunction
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An improved understanding of the mechanisms of endothelial dysfunction and hypoxia may
lead to novel therapies. Endothelial glycocalyx deterioration may be prevented by
angiotensin 2 inhibition and mycophenolate can inhibit PDGF-B production (155). ACE
inhibitors also reduce endothelial activation by increasing NO production independently of
their anti-hypertensive effects (76). Podocytes lacking both endothelin receptors are
protected from damage in animal models of diabetes and an endothelin antagonist reduced
proteinuria in patients with diabetic nephropathy (156). Targeting of VEGF-A (157) or
PDGF has proved more challenging because the relationships between angiogenesis,
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inflammation and fibrosis are still not fully understood. For example, some proangiogenic
factors also enhance inflammation or fibrosis (76) and PDGF may be involved in tubular
regeneration (85). In addition angiogenesis may be detrimental early in disease, helping to
mediate glomerular hypertrophy, before becoming dysfunctional at later stages (76).
Preventing and reversing renal fibrosis
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Several strategies for preventing or reversing renal fibrosis are in clinical development and
include monoclonal antibodies to TGFβ and CTGF or their downstream signaling pathways,
growth factor antagonists such as BMP-7 mimetics, phosphodiesterase inhibitors and
NADPH oxidase inhibitors (85, 158). Nevertheless, the wide array of potentially profibrotic
factors that arise in inflamed kidneys (87) suggest that broad approaches may be needed.
One exciting new therapeutic area is the prevention of tubular epithelial injury based on a
better understanding of the mechanisms of tubular stress. Data from mouse models suggests
that pharmacologic enhancement of fatty acid oxidation may protect tubules from death and
help prevent fibrosis (82).
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Reparative macrophages that arise during the healing phase of acute inflammation may act
to reverse early fibrosis by endocytosis and degradation of collagen (159) or by secreting
enzymes that break down collagen and matrix. These macrophages can also stimulate
tubular epithelial cell regeneration through a mechanism involving the Wnt pathway (160).
Importantly however, prolonged exposure to reparative macrophages may cause renal
fibrosis or excessive remodeling (161). Strategies targeting dysfunctional macrophage repair
have included antagonism of the interstitial macrophage receptor CCR1 and of the resident
macrophage receptor CX3CR1 (162). More effective targeting of macrophages awaits a
better understanding of how their inflammatory, pro-fibrotic and reparative functions are
regulated during the various stages of disease.

Conclusions

Author Manuscript

Progress continues to be made in our understanding of the mechanisms of acute and chronic
renal injury as they pertain to LN. Although immunosuppressive agents continue to be the
mainstay of treatment, new biologic agents continue to be tested and development of
treatments that protect the kidneys against endothelial and tubular injury and fibrosis may
help prevent chronic damage. Progress in developing new therapies for LN will require the
formation of LN consortia, patient and physician engagement in research protocols,
improved clinical trial design, improved definitions of renal outcome that may include
second biopsies, testing of molecular and proteomic analyses in clinical trials and, finally,
strategies for prevention and treatment based on these results. The most cost effective
current approach involves early recognition (163) with prompt intervention and treatment of
reversible risk factors. This requires ensuring access both to properly trained health care
providers and to medications and is the necessary foundation upon which individualized care
can eventually be built.
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•

Lupus nephritis remains a major cause of morbidity and mortality in SLE with
approximately 40% of affected individuals developing some degree of renal
impairment.

•

Long term prognosis is influenced by both extrinsic and intrinsic renal factors
and depends on the severity of disease at presentation, the response to
immunosuppressive therapy and access to high quality healthcare

•

Current methods for classifying LN are based solely on light microscopy of
kidney biopsies and do not adequately predict response to therapy or long term
outcomes. Additional phenotyping based on mechanisms of injury may improve
clinical decision making.

•

Mechanisms of renal injury involve both local immune responses and aberrant
responses by the renal parenchyma including disruption of cell-cell interactions
that maintain nephron structure, loss of renal microvasculature, tubular atrophy
and renal fibrosis. Some of these processes are not reversible with
immunosuppressive therapy and may require different approaches based on
targeting non-immune mechanisms for disease progression.

•

Although LN is initiated by immune complex deposition, the response to injury
in individual patients is variable and may reflect the balance of innate vs
adaptive immunity, inflammation vs metabolic changes, the degree of hypoxia
and the capacity for regeneration and fibrosis.

•

Genetic analyses, molecular profiling and proteomic analyses are being used to
discover mechanisms of renal injury and suggest new and more individualized
therapeutic approaches.

•

Studies in mouse models show that progression to CKD is not inevitable even if
systemic autoimmunity persists and that several checkpoints in the progression
pathway are susceptible to therapeutic intervention.

•

Because clinical remission and renal histologic remission are not always
correlated, improved disease monitoring and/or second biopsies may help
identify patients at risk of progression and in need of more intense maintenance
therapy
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Figure 1.
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Glomerular injury in LN: View of a glomerular loop containing endothelial cells (yellow)
lined by a glycocalyx (orange), mesangial cells (ochre) and podocytes (brown). Podocytes
are separated from endothelial cells by the glomerular basement membrane (GBM -red). The
glomerulus is contained by Bowman’s capsule (BC) that is lined by parietal epithelial cells.
Immune deposits (blue) may be found in the mesangium, subendothelium, or subepithelium.
Subendothelial deposits are in contact with the vascular space (V) and can recruit myeloid
cells (My) into the renal parenchyma. Subepithelial cells are in contact with podocytes and
the urinary space (U). Podocytes and endothelial cells communicate with each other by
transfer of soluble growth factors across the GBM, whereas mesangial cells and endothelial
cells can interact directly via receptors and their ligands. Alterations of these factors in LN
are shown by the arrows and color coded according to cell type.
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Figure 2.

Interstitial injury in LN: A single nephron with its tubular and capillary system is shown.
Cellular components that contribute to interstitial injury include tubular cells, endothelial
cells (Cap), pericytes (P), fibrobasts (F), inflammatory lymphocytes (Ly), infiltrating and
resident macrophages (Mac) and infiltrating dendritic cells (DC). Both pericytes and
fibrobasts can differentiate into myofibroblasts (Myo). The sequential processes occurring
during the progression to CKD are shown on the right and key molecules are shown on the
left.
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Figure 3.

Shared pathogenic pathways identified in the kidneys of the three different lupus-prone
mouse strains. NZB/W and NZW/BXSB mice develop proliferative glomerulonephritis and
NZM2410 mice develop glomerulosclerosis with limited inflammation. Pathways that are
shared between all three strains and human LN are shown in green. The major functional
pathway that is overrepresented in each of the three individual strains is shown in purple.
Transcription factors are shown in blue and other pathways shared by two strains are shown
in black. (adapted from (122))
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Factors associated with poor prognosis in LN (7, 9, 11–12, 54, 97–98, 164)
Renal extrinsic
Genetic
African-American race
Male gender
Older age
Socio-economic
Delay in diagnosis
Poor compliance
Limited access to qualified providers
Lack of health insurance
Renal intrinsic
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ISN/RPS histologic classes III, IV and V
Increased serum creatinine
Interstitial infiltrates
Fibrosis
Mixed renal intrinsic/extrinsic
Anemia
Hypertension
Inadequate response to therapy
Failure to resolve proteinuria by 6–12 months
Recurrence
Inflammation, macrophage infiltration, fibrosis at second biopsy
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Potential targets of therapy in LN (76, 147, 154, 158, 162, 165)
Immune based therapies
Innate immune mechanisms, eg inflammasome
Adaptive immunity eg costimulatory blockade
Effector cells, eg plasma cells, macrophages
Effector pathways, eg alternative complement pathway, TWEAK/Fn14 pathway
Soluble inflammatory mediators, eg cytokines/chemokines
Signaling molecules eg, kinases, mTOR
Protection of intrinsic renal cells
Renin angiotensin system
Endothelin 1
Growth factors, eg PDGF
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Oxidative stress, eg NADP oxidases
Improved microcirculation
Phosphodiesterase 5
Anti-fibrotics
Growth factors, eg TGFβ, CTGF
Growth factor antagonists, eg HGF mimetic, BMP7 mimetic
Others
Epigenomic reprogramming
Mesenchymal stem cells
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